Transactive response DNA binding protein 43 (TDP-43) plays a central role in the neuropathology of frontotemporal lobar degeneration and amyotrophic lateral sclerosis, but the relationship between TDP-43 abnormalities and Alzheimer disease (AD) remains unclear. To determine whether TDP-43 can serve as a neuropathologic marker of AD, we performed biochemical characterization and quantification of TDP-43 in homogenates from parietal neocortex of subjects with a clinical diagnosis of no cognitive impairment (NCI, n = 12), mild cognitive impairment (MCI, n = 12), or AD (n = 12). Immunoblots revealed increased detergent-insoluble TDP-43 in the cortex of 0, 3, and 6 of the 12 individuals with NCI, MCI, or AD, respectively. Detergent-insoluble TDP-43 was positively correlated with the accumulation of soluble AA 42 , amyloid plaques, and paired helical filament tau. In contrast, phospho-TDP-43 was decreased in the cytosolic fraction and detergent-soluble membrane/nuclear fraction from AD patients and correlated with antemortem cognitive function. Immunofluorescence analysis confirmed that the frequencies of individuals with TDP-43 or phospho-TDP-43 cytoplasmic inclusions were higher in AD than in NCI, with MCI at an intermediate level. These data indicate that abnormalities of TDP-43 occur in an important subset of MCI and AD patients and that they correlate with the clinical and neuropathologic features of AD.
INTRODUCTION
Transactive response (TAR) DNA binding protein proteinopathy is one of the rapidly evolving topics in neurodegenerative disease research. This protein, which is normally found in the cell nucleus, is the major component of the ubiquitin-positive neuronal cytoplasmic inclusions that are hallmarks of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U, now designated FTLD-TDP) and amyotrophic lateral sclerosis (ALS) without superoxide dismutase 1 mutation (1Y6). Since 2008, at least 38 mutations in the gene encoding TDP-43 have been found in people with familial and sporadic ALS and FTLD-TDP, supporting a causative role for TDP-43 in the neurodegenerative processes underlying these diseases (7, 8) . Most forms of sporadic ALS and FTLD-TDP are now collectively referred to as TDP-43 proteinopathies (7, 9, 10) .
TDP-43 is a DNA-and RNA-binding protein that is normally found in the nucleus and is involved in the regulation of gene expression by controlling several processes, including gene transcription, RNA splicing, messenger RNA stabilization and transport, microRNA binding and regulation (11Y13). The pathogenicity of TDP-43 involves the perturbation of its trafficking between the nucleus and the cytoplasm, where it becomes sequestered as insoluble aggregates (7, 14, 15) . Indeed, nuclear staining of TDP-43 is significantly reduced in neurons that bear cytoplasmic ubiquitin-positive inclusions (3, 5, 16) . Moreover, pathologic TDP-43 is cleaved to generate ubiquitinated and hyperphosphorylated 35-and 25-kd C-terminal fragments (17, 18) .
The relationship between TDP-43 and Alzheimer disease (AD) has not been clearly defined yet. Qualitative analyses report the presence of TDP-43 immunostained aggregates in between 14% and 57% of AD brains examined (19Y30) and even up to 75% in advanced stage AD patients (27) . Using antibodies specifically targeting phosphorylated and/or Cterminal fragments, TDP-43Ypositive cytoplasmic inclusions can be detected in brain sections from AD cases (22, 27, 30) ; however, these studies used qualitative immunohistochemical and histological techniques and did not distinguish between soluble and insoluble protein fractions.
Mild cognitive impairment (MCI) is a general term used to describe mild cognitive deficits of insufficient severity to warrant a diagnosis of dementia in elderly people; in many cases, this represents an early sign of developing AD (31) . The neuropathologic substrate of MCI is not well defined J Neuropathol Exp Neurol Volume 70, Number 9, September 2011 owing to the low availability of brain samples from individuals who died at the time they experienced the condition. Nevertheless, most studies report that individuals with MCI show levels of A-amyloid (AA) and tau pathologies at intermediate levels between AD and controls (32Y34). To our knowledge, no quantitative assessment of the accumulation of TDP-43 in preclinical AD has been performed.
Clinicopathologic studies have established the importance of amyloid plaques and neurofibrillary pathology in AD but have also revealed imperfections in the correlation between AA and tau and cognitive decline (35Y38). Although the complexity of the disease may explain these inconsistencies, it is conceivable that other neuropathologic events contribute significantly to the AD. To determine whether TDP-43 can be considered a neuropathologic marker of AD and/or MCI in comparison with AA and tau, we performed biochemical quantification of TDP-43 in brain homogenates from individuals with AD or MCI. Biochemical data were also correlated with qualitative analysis of TDP-43 and phospho-TDP-43 cytoplasmic immunofluorescence. Our principal aim was to investigate the relationship between clinical diagnosis, antemortem cognitive function, the extent of AA and tau neuropathology, and the accumulation of TDP-43 in the parietal cortex.
MATERIALS AND METHODS

Antibodies and Reagents
The following antibodies were used in this study: antiactin (ABM, Richmond, Canada), antiYtau 13 (Covance, Princeton, NJ), antiYtau CP-13 (phosphorylated at serine 202/ threonine 205, gift from Dr Peter Davies; Albert Einstein College of Medicine, Bronx, NY), antiYC-TDP-43 (12892 polyclonal antibody to C-terminal TDP-43; Proteintech Group, Chicago, IL), antiYTDP-43 2E2-D3 (human-specific monoclonal antibody to total TDP-43; Abnova, Walnut, CA [39] ), antiYN-TDP-43 (polyclonal antibody to N-terminal TDP-43; Cosmo Bio, Carlsbad, CA), antiYTDP-43 pS403/S404 (polyclonal antibody to phosphorylated serine 403/serine 404 TDP-43; Cosmo Bio), antiYTDP-43 pS409/S410 (polyclonal antibody to phosphorylated serine 409/serine 410 TDP-43; Cosmo Bio), and anti-tubulin (ABM). All biochemical reagents were purchased from J.T. Baker (Phillipsburg, NJ) unless otherwise specified.
Study Participants
Samples from the brain cortex were obtained from participants in the Religious Order Study, a longitudinal clinicopathologic study of aging and dementia from which an extensive amount of clinical and neuropathologic data were available (40) . The study included participants with the clinical diagnosis of MCI (n = 12), AD (n = 12), and persons with no obvious cognitive impairment (NCI, n = 12), as previously described (32) . Each participant had undergone uniform structured baseline clinical evaluation and annual follow-up evaluation until death (33) . Briefly, dementia and AD diagnosis required evidence of meaningful decline in cognitive function and impairment on at least 2 cognitive domains (for AD, 1 domain had to have been episodic memory), based on the results of 21 cognitive performance tests and their review by a clinical neuropsychologist and expert clinician. ''MCI'' refers to participants with cognitive impairment as assessed by the neuropsychologist but without a diagnosis of dementia, as determined by the clinician. At death, a neurologist, blinded to all postmortem data, reviewed all available clinical data and rendered a summary diagnostic opinion regarding the clinical diagnosis at the time of death (41Y43).
At death, each case was assigned a Braak score based on neuronal neurofibrillary tangle pathology (44), a neuritic plaque score based on the modified Consortium to Establish a Registry for Alzheimer Disease (CERAD) criteria (excluding age and clinical diagnosis), and an AD pathologic diagnosis based on the National Institute on Aging Y Reagan criteria by examiners blinded to all clinical data (33) . Neuritic plaques, diffuse plaques, and neurofibrillary tangles in the inferior parietal cortex were counted after Bielschowsky silver staining, as previously described (45) . Concentrations of AA and tau in the parietal cortex were assessed using enzymelinked immunosorbent assay (ELISA) and Western immunoblotting as described (32) . Table 1 summarizes clinical and neuropathologic data of subjects grouped by the clinical diagnosis. A global measure of cognition was attributed to each patient based on 19 cognitive performance tests and could also be summarized as cognitive abilities in 5 domains: episodic memory, semantic memory, working memory, perceptual speed, and visuospatial ability (46) .
Protein Lysates Preparation
Postmortem samples (È100 mg) from the inferior parietal cortex from these 36 study volunteers were homogenized and centrifuged sequentially to generate a Tris-buffered saline (TBS)Ysoluble protein fraction that contains intracellular (cytosolic) and extracellular proteins, a detergent-soluble protein fraction containing membrane-bound and nuclear proteins and a detergent-insoluble protein fraction (formic acid extract) as described (32) . Briefly, tissue samples were homogenized in 4 volumes (Kl/mg tissue) of TBS buffer (50 mmol/L TrisHCl, 138 mmol/L NaCl, 2.7 mmol/L KCl containing Complete Protease Inhibitor Cocktail [Roche, Indianapolis, IN], 10 Kg/ml pepstatin A, 0.1 mmol/L EDTA, and 1 mmol/L each of sodium vanadate and sodium pyrophosphate as phosphatase inhibitors), then sonicated 3Â for 5 Â 1-second pulse. The solution was then spin at 100,000 Â g for 20 minutes at 4-C. The supernatant, the TBS-soluble fraction, was removed and kept at j80-C until needed. The pellet was homogenized in lysis buffer (150 mmol/L NaCl, 10 mmol/L NaH 2 PO 4 , 0.5% sodium deoxycholate, 0.5% sodium dodecyl sulfate [SDS], 1% Triton X-100 containing the same protease and phosphatase inhibitors), sonicated, and spin as previously described. After removing the supernatant (detergent-soluble protein fraction), the pellet was homogenized in 4 volumes (Kl/mg pellet) formic acid, sonicated for 10 Â 1-second pulse and spin at 10,000 Â g for 20 minutes at 4-C. The supernatant (detergent-insoluble protein fraction) was removed and separated in aliquots, the protein concentration was measured, and the proteins were dried using a SpeedVac (Thermo Savant, Waltham, MA). For ELISA, the proteins were solubilized in guanidine 5 mol/L. Proteins for Western immunoblotting were solubilized in Laemmli loading buffer (60 mmol/L Tris, 10% glycerol, 2% SDS, 0.0025% bromophenol blue, 2.5% Amercaptoethanol, pH 8.5) and kept at j80-C until needed. Protein concentration for all fractions was determined using bicinchoninic acid assay (Pierce, Rockford, IL).
Western Immunoblotting and ELISA
TDP-43 and tau were quantified in the TBS-soluble, detergent-soluble, and detergent-insoluble fractions of brain homogenates using Western immunoblot. Proteins (15 Kg/ sample) were heated at 95-C for 5 minutes in Laemmli loading buffer and separated by SDS-PAGE on an 8% polyacrylamide gel, transferred on a polyvinylidene fluoride membrane (Immobilon-P; Millipore, Billerica, MA), and blocked in 5% nonfat dry milk, 0.5% bovine serum albumin, 0.1% Tween 20 in phosphate-buffered saline (Bioshop Canada, Inc, Burlington, Ontario, Canada), as previously described (32) . Proteins were detected using appropriate primary antibody followed by horseradish peroxidaseYlabeled secondary antibody and chemiluminescence reagents (Lumiglo Reserve; KPL, Gaithersburg, MD). Band intensities were quantified using a KODAK Imaging Station 4000 MM Digital Imaging System (Molecular Imaging Software version 4.0.5f 7; Carestream Health, Rochester, NY).
A-Amyloid 40 (AA 40 ) and 42 (AA 42 ) concentrations were measured using specific human AA ELISA Kits from Wako (Osaka, Japan), according to the manufacturer's recommendations. The plates were read at 450 nm using a Synergy HT multidetection microplate reader (Biotek, Winooski, VT).
Immunofluorescence Staining
Immunofluorescence labeling was performed on 6-Kmthick sections of paraffin-embedded parietal cortex samples from the Religious Order Study. Before immunostaining, the sections were microwaved 2 Â for 2 minutes each in 0.01 mol/L citrate buffer, pH 6.0, for antigen retrieval. AntiYN-TDP-43 and antiYTDP-43 pS409/S410 were used as primary antibodies and processed as previously described (47) . The nuclei were counterstained with 4 ¶,6-diamidino-2-phenylindole (Pierce) for differentiation of cytoplasmic or nuclear TDP-43 staining. An analysis of each section was performed to determine the presence of extranuclear TDP-43 staining. Scores between 0 and 3 (0 = none, 1 = rare or mild, 2 = moderate, 3 = severe) were assigned to each section for the presence of cytoplasmic TDP-43 staining with the phosphorylation-dependent and -independent antibody. Assessment was performed by an observer (C.T.) who was blinded to clinical and neuropathologic diagnoses. Sections with abundant intracellular sources of autofluorescence, such as lipofuscin pigments, were frequently found and were excluded.
Data Analysis
Statistical comparisons of data between groups were performed depending on the normality of distribution and variances equivalence between groups. In cases of equal variance and normal distribution, we used analysis of variance (ANOVA) followed by post hoc pairwise comparisons (e.g. Tukey-Kramer) when appropriate. When homogeneity of variance was not confirmed (p 9 0.05 using the Bartlett test), Welch ANOVA followed by Dunnett post hoc test was performed. Variances were reduced using logarithmic transformations to provide more normally distributed measures when needed. Otherwise, Kruskal-Wallis independent-group comparisons were performed followed by Dunn multiple comparison tests. For comparisons between 2 groups, Mann-Whitney test was performed. Finally, coefficient of determination (r 2 ) and the significance of the degree of linear relationship between various parameters were determined with a simple regression model. Statistical analyses were done using JMP Statistical Analysis Software (version 8.0.2; SAS Institute Inc., Cary, NC).
RESULTS
Clinical and neuropathologic data of the study participants are summarized in Table 1 . As expected, individuals with AD showed significant cognitive deficits as assessed with Mini Mental State Examination (MMSE) and global cognition measures based on 19 cognitive performance tests versus persons with MCI and NCI. The accumulation of tau, PHF tau , and AA 42 in the cerebral cortex was more prominent in AD despite important interindividual variation (Table 1) .
Proteinopathy has been associated with the conversion of pathogenic protein/peptide to insoluble aggregates. Hence, we first focused on the quantification of TDP-43 in the detergent-insoluble fraction in which TDP-43 aggregates are expected. Using 3 different antibodies, we determined that concentrations of detergent-insoluble TDP-43 were higher in an important subset of persons with MCI or diagnosed with AD ( Fig. 1) . Although a nonparametric distribution-free analysis with a Kruskal-Wallis test confirmed the increase in detergentinsoluble TDP-43 in the AD group (p G 0.05; Fig. 1A ), the concentration of insoluble TDP-43 displayed a bimodal distribution, rendering statistical comparison hazardous. Indeed, only a few MCI or AD cases had increased levels, whereas most remained comparable to controls (Figs. 1AYE) . For example, the concentrations of TDP-43 in Subjects 3, 5, and 10 from the MCI group were consistently elevated (Figs. 1AYE).
To better assess these differences between groups, we compared the proportion of individuals with a high level (as defined as a relative OD 9 4) of TDP-43 using a contingency table with data combined from all experiments (Fig. 1E) . Data from the 3 experiments were combined by expressing individual data to their respective controls. We found that the proportion of samples with a high level of TDP-43 was significantly increased in AD (Fig. 1F) . Indeed, 3 of 12 (25%) and 6 of 12 (50%) individuals with a clinical diagnosis of MCI and AD, respectively, had high concentrations of detergent-insoluble TDP-43, whereas this was not the case in any of the controls (Figs. 1E, F) . In addition, correlative analyses showed that detergent-insoluble TDP-43 was associated with an antemortem level of perceptual speed, a measure of executive function (Table 2) , with increased AA and tau pathologies (Table 3) , but not with the neuropathologic diagnosis of AD ( We next wanted to determine whether the above changes were associated with alterations of TDP-43 in the fractions containing TBS-soluble cytosol and extracellular proteins and the fractions with detergent-soluble membrane and nuclear proteins. No significant differences in TDP-43 and its 35-kd fragment were detected in either TBS or detergent-soluble fractions (Fig. 2) . Nevertheless, we observed a weaker TDP43Ypositive 190-kd band, which could represent an oligomeric form of TDP-43. Alternatively, it could be an SDS-resistant TDP-43/protein-and/or RNA-complex associated with normal physiological function of TDP-43. Interestingly, this higher molecular weight TDP-43-positive band was decreased in AD (j48% versus NCI, p = 0.019, Kruskal-Wallis test).
The pathogenicity of TDP-43 has been associated with its phosphorylation. Much interest is devoted to the 25-kd C-terminal fragment of TDP-43, which is more prone to phosphorylation at S409/S410 and is particularly neurotoxic in vitro (17, 48) . Hence, we investigated the concentration of phospho-TDP-43 in our samples. In the formic acid extracts containing detergent-insoluble proteins, the signal was relatively weak, perhaps due to a partial loss of phospho-epitopes during the tissue preparation steps. However, both the 43-and 25-kd bands were detected and quantified, revealing no major differences between groups (Fig. 3) . Nevertheless, the 25-kd phosphorylated C-terminal fragment of TDP-43 showed a trend toward an increase in AD and was relatively high in the same 3 patients with MCI (Subjects 3, 5, and 10) (Fig. 3B) . The 25-kd fragment was also positively associated with accumulation of detergent-insoluble AA 42 (r 2 = +0.09, p G 0.05; Table 3 ).
Soluble protein fractions were also subjected to immunoblot for phospho-TDP-43, and several significant alterations were detected. First, the TBS-soluble phospho-TDP-43 was increased in MCI versus NCI (+35%, p = 0.0304, MannWhitney) but showed an abnormal distribution in the AD group (Fig. 4A) . Second, the 35-kd phospho-TDP-43 fragment remained high in the cortex of persons with MCI but was decreased in AD (j47% compared with MCI, p G 0.01, Welch ANOVA, Dunnett post hoc test; Fig. 4B ). Finally, we observed a significant decrease of phospho-TDP-43 in the detergent-soluble fraction (j21% compared with NCI, p G 0.05, Welch ANOVA, Dunnett post hoc test; Fig. 4C ). Detergent-soluble phospho-TDP-43 was decreased in individuals with a neuropathologic diagnosis consistent with a high likelihood AD (Braak IV-V and Reagan) (Table, Supplemental Digital Content 1, http://links.lww.com/NEN/A261) (44) .
Next, we performed correlative analysis between soluble phosphorylated species and both levels of cognition and neuropathology. We first found a significant relationship between the TBS-soluble 35-kd fragment and detergent-soluble full-length TDP-43 with cognitive performance before death, particularly strong with episodic memory (r 2 = +0.18, p G 0.01; Table 2 ). In addition, the TBS-soluble phospho-TDP-43 35-kd fragment was inversely correlated with soluble AA 42 , whereas concentration of detergent-soluble phospho-TDP-43 was inversely associated with soluble AA 42 , amyloid plaques, PHF tau levels, and tangle counts (Table 3) .
To evaluate the subcellular distribution of TDP-43, we performed immunofluorescence staining using antibodies targeting TDP-43 ( Fig. 5) and phospho-TDP-43 (Fig. 6 ) on paraffin-embedded sections from the parietal cortex from the same series of samples. Additional objectives included the comparison of our biochemical measurements with a qualitative immunofluorescence approach and with the available literature. As expected, TDP-43 was normally found in the nucleus (Figs. 5C, D, and 6E, F) . The frequencies of cytoplasmic TDP-43 immunolabeling were increased in MCI and AD, indicating the presence of an abnormal redistribution of TDP-43. Indeed, numerous TDP-43 inclusions were observed in 8%, 33%, and 55% of persons with NCI, MCI, and AD, respectively (W 2 = 0.057; Fig. 5 ). When assessing phospho-TDP-43, the difference between groups became more definite as the frequencies of phospho-TDP-43Ypositive cytoplasmic inclusion were 0%, 8%, and 55% in NCI, MCI, and AD, respectively (W 2 = 0.007; Fig. 6 ). The frequency of phospho-TDP-43Ypositive cytoplasmic inclusion showed a significant association with the concentration of TDP-43 in the detergentinsoluble fractions (r 2 = +0.38, p = 0.0002) but an inverse relationship with TBS-soluble TDP-43 (r 2 = j0.13, p = 0.031), underscoring the importance of the conversion from soluble TDP-43 to aggregates (Table 3) . On the other hand, TDP-43 cytoplasmic inclusions did not correlate with the neuropathologic diagnosis of AD (Table, Supplemental Digital Content 1, http://links.lww.com/NEN/A261). Strikingly, however, our assessment of phospho-TDP-43Ypositive cytoplasmic inclusion showed a very strong inverse relationship with antemortem global cognitive (r 2 = j0.27, p = 0.0028), especially in the sphere of perceptual speed (r 2 = j0.35, p = 0.0005, Table 2 ). Similar, but less robust, correlations were detected with total TDP-43Ypositive cytoplasmic labeling (Table 2) . These correlative analyses with cognitive function emphasize 
DISCUSSION
The present study revealed important biochemical and subcellular alterations of TDP-43 in an important proportion of persons with MCI or AD; the data suggest that they may contribute to the expression of cognitive impairment and could explain some inconsistencies between neuropathology and clinical impairment in individuals with MCI or AD.
Is TDP-43 Altered in MCI?
To our knowledge, TDP-43 has not been previously investigated in MCI. In general, TDP-43 changes observed here did not reach statistical significance and were at an intermediate level between NCI and AD. However, phosphorylated TDP-43 in the TBS fraction was higher in MCI Can TDP-43 Be Considered a Neuropathologic Marker of AD?
To answer that question, it is essential to put it in the general context of MCI and AD neuropathology. Amyloid and tau pathologies are the well-accepted hallmarks of AD. However, postmortem quantification has revealed that accumulations of AA and tau are highly variable in most individuals with MCI or AD (32, 38, 49) . In addition, significant accumulation of AA and neuritic plaques has been described in persons with no cognitive impairment (32, 36, 50) , suggesting that there are additional factors that contribute to the expression of dementia. A relative absence of postmortem tau deposition or neurofibrillary tangles has also been observed despite the antemortem clinical diagnoses of AD (32, 50, 51) , showing that the clinical AD phenotype may be expressed by other pathologic processes. Thus, the interindividual variation and the lack of clear differences between groups observed here for TDP-43 in both the MCI and AD groups is similar in some respects to that described for AA and tau. Nevertheless, it was clear in the present study that TDP-43 pathologic abnormality was more commonly found in persons with MCI and AD.
Proteinopathy-associated neurodegenerative diseases are characterized by the conversion of the pathogenic protein/ peptide into insoluble aggregates. For example, we and others have found that insoluble stable deposits of AA and tau are strongly associated and particularly well correlated with antemortem cognitive impairment (32, 52Y54). As for tau, AA, and >-synuclein, TDP-43 forms insoluble deposits in the brain or spinal cord of ALS and FTLD patients (3, 4, 18, 55Y58) . The accumulation of detergent-insoluble TDP-43 in the parietal cortex was more frequent in individuals with MCI (25%) or AD (50%) compared with controls (NCI, 0%) based on a semiquantitative assessment using Western immunoblots. In agreement with the present results, data accumulated so far with qualitative immunohistochemical assessment suggest that between 14% and 57% of cases with a pathologic diagnosis of AD have evidence of TDP-43 pathologic abnormality (19Y30). As in ALS and FTLD-TDP, the TDP-43Y positive inclusions in AD brains are mostly cytoplasmic. We also reported the presence of a 25-kd caspase-cleaved TDP-43 fragment, in accordance with others (29, 57) , consistent with the extensive amount of evidence showing caspase activation during AD progression (59Y64). In cell culture systems, the caspase-processed C-terminal fragments of 35 and 25 kd can be produced on induction of apoptosis (65) , and the aggregationprone 25-kd C-terminal fragment results in abnormal TDP-43 cytosolic localization and increase in cellular toxicity, possibly through a toxic gain-of-function mechanism (17) .
Similarly to tau, abnormal phosphorylation has been consistently associated with pathologic TDP-43 (3, 18, 56, 58) . In AD, phospho-TDP-43 was detected in 14% (30), 36%, and 56% (22) individuals in 3 independent series. Likewise, we identified phospho-TDP-43Ypositive cytoplasmic inclusions in 50% of AD (6/12) and 8% of MCI patients (1/12) using immunofluorescence measurements. In contrast, we observed a decrease of phospho-TDP-43 levels in the detergent-soluble fractions, consistent with the hypothesis that nuclear TDP-43 is translocated into insoluble deposits in AD. Hence, the present data argue for a scheme in which, during AD pathogenesis, phosphorylated TDP-43 species decrease in the cytosolic and nuclear fraction to progressively accumulate in detergentinsoluble aggregates. On one hand, the diminution of phosphorylated TDP-43 in TBS and detergent-soluble fractions correlates with cognitive deterioration and accumulation of amyloid and tangle pathologies. On the other hand, severe deposition of TDP-43 was observed more frequently in MCI and AD, a phenomenon associated with both amyloid and tangle pathologies as well. Overall, alterations in TDP-43 are common but seem not to be necessary in clinical and pathologic AD. Similar to MCI, it remains unclear whether TDP-43 proteinopathy in AD represents an additional neuropathologic marker of AD or, alternatively, is revealing the presence of a coexisting FTLD disease.
Which TDP-43 Form Correlates Better With AD Neuropathology or Cognitive Impairment?
The present clinicopathologic study allowed us to compare the value of different assessment of TDP-43. A strong correlation between the accumulation of detergent-insoluble TDP-43 and key markers of AD neuropathology, including amyloid deposition and PHF tau , was observed. Mapt (coding for tau) have been recently identified among TDP-43 RNA targets (66) . It is conceivable that a loss of normal TDP-43 function could be associated to tau RNA dysregulation and increase tau pathologic abnormality in AD. Nevertheless, the neuropathologic diagnosis of AD did not accurately predict the amount of detergent-insoluble TDP-43 in the parietal cortex, which remained poorly associated with cognitive scores, except perhaps with perceptual speed. Alteration of phospho-TDP-43 in soluble fractions correlated better than insoluble TDP-43 with cognition, especially with episodic memory, although still showing good association with pathology, especially with soluble AA 42 . Interestingly, TDP-43Ypositive cytoplasmic inclusions correlated particularly well with perceptual speed, a measure of executive function, contrasting with AA and tau, which show the strongest association with episodic memory (32) . This differential cognitive profile, which is more typical of frontotemporal lobar degeneration rather than AD, may indicate that TDP-43 abnormalities may have a unique cognitive phenotype.
Unexpectedly, immunofluorescence assessment of cytoplasmic TDP-43 correlated better with antemortem evaluation of cognitive performance. Cytoplasmic TDP-43 immunofluorescence on paraffin-embedded sections from the parietal cortex was clearly more common in AD than in NCI. Despite the fact that our immunofluorescence measurements were essentially qualitative, the presence of cytoplasmic TDP-43 was highly correlated with cognitive assessment. Such association was even stronger when using antibodies specifically targeting phosphorylated TDP-43, suggesting that immunofluorescence evaluation of TDP-43 neuropathologic abnormality on brain sections is a reliable approach. Overall, our immunofluorescence measurements indicate that, despite the use of nonquantitative parameters, the presence of cytoplasmic inclusions of TDP-43 determines its relationship with cognition scores and that this can be achieved only with histologic evaluation of brain sections.
CONCLUSIONS
This clinicopathologic study confirmed that TDP-43 pathologic abnormality occurs in an important subset of AD patients. Our observations are consistent with a pathogenic scheme in which nuclear/cytoplasmic soluble phospho-TDP-43 is decreased along with an increased deposition of detergentinsoluble TDP-43 and the deposition of amyloid and tau pathologic abnormality. The translocation of TDP-43 into the cytoplasm, which can be assessed by immunohistochemical analysis of brain sections, is a very good technique to assess TDP-43 neuropathologic abnormality and correlates best with cognitive function. Furthermore, the presence of TDP-43 pathologic abnormality in a subset of MCI patients could imply that TDP-43 impairment is an early event in the evolution of clinical AD.
In summary, our results confirm and further describe the alterations of TDP-43 in clinical and pathologic AD; they provide new data on a role for TDP-43 alterations in MCI and show that TDP-43 alterations have a complex relationship with the hallmark pathologies of AD, AA and tau. The exact role of TDP-43 pathologic abnormality in the pathogenesis of clinical and neuropathologic AD should be the focus of further studies.
